0000899243-18-007986.txt : 20180319
0000899243-18-007986.hdr.sgml : 20180319
20180319172611
ACCESSION NUMBER: 0000899243-18-007986
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180319
FILED AS OF DATE: 20180319
DATE AS OF CHANGE: 20180319
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KANEKO YASUNORI
CENTRAL INDEX KEY: 0001277503
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38419
FILM NUMBER: 18699879
MAIL ADDRESS:
STREET 1: 509 ROEHAMPTON
CITY: HILLS BOROUGH
STATE: CA
ZIP: 94010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arcus Biosciences, Inc.
CENTRAL INDEX KEY: 0001724521
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473898435
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3928 POINT EDEN WAY
CITY: HAYWARD
STATE: CA
ZIP: 94545
BUSINESS PHONE: 650-489-9000
MAIL ADDRESS:
STREET 1: 3928 POINT EDEN WAY
CITY: HAYWARD
STATE: CA
ZIP: 94545
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-03-19
0
0001724521
Arcus Biosciences, Inc.
RCUS
0001277503
KANEKO YASUNORI
C/O ARCUS BIOSCIENCES, INC.
3928 POINT EDEN WAY
HAYWARD
CA
94545
1
0
0
0
Common Stock
2018-03-19
4
C
0
505050
A
505050
I
By Kaneko Capital, LLC
Common Stock
2018-03-19
4
C
0
252524
A
252524
I
By Kaneko Investments, LLC
Common Stock
2018-03-19
4
C
0
33818
A
96948
I
By Trust
Series A Convertible Preferred Stock
2018-03-19
4
C
0
505050
D
Common Stock
505050
0
I
By Kaneko Capital, LLC
Series B Convertible Preferred Stock
2018-03-19
4
C
0
252524
D
Common Stock
252524
0
I
By Kaneko Investments, LLC
Series B Convertible Preferred Stock
2018-03-19
4
C
0
31253
D
Common Stock
31253
0
I
By Trust
Series C Convertible Preferred Stock
2018-03-19
4
C
0
2565
D
Common Stock
2565
0
I
By Trust
The total represents shares received upon conversion of shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock.
The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q
/s/ Scott Paraker, Attorney-in-Fact
2018-03-19